<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Neuropsychiatr Dis Treat</journal-id><journal-id journal-id-type="iso-abbrev">Neuropsychiatr Dis Treat</journal-id><journal-id journal-id-type="publisher-id">ndt</journal-id><journal-title-group><journal-title>Neuropsychiatric Disease and Treatment</journal-title></journal-title-group><issn pub-type="ppub">1176-6328</issn><issn pub-type="epub">1178-2021</issn><publisher><publisher-name>Dove</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">PMC9438797</article-id><article-id pub-id-type="publisher-id">369412</article-id><article-id pub-id-type="doi">10.2147/NDT.S369412</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Intranasal Administration of Brain-Derived Neurotrophic Factor Rescues Depressive-Like Phenotypes in Chronic Unpredictable Mild Stress Mice</article-title><alt-title alt-title-type="running-authors">Li et al</alt-title><alt-title alt-title-type="running-title">Li et al</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Li</surname><given-names>Xiao-Ling</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ft0001" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Liu</surname><given-names>Hua</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="ft0001" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Shu-Han</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7529-4408</contrib-id><name><surname>Cheng</surname><given-names>Yong</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="an0001" ref-type="corresp"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8598-9262</contrib-id><name><surname>Xie</surname><given-names>Guo-Jun</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="an0002" ref-type="corresp"/></contrib><aff id="aff0001"><label>1</label><institution>The Third People&#x02019;s Hospital of Foshan</institution>, <addr-line>Foshan</addr-line>, <country>People&#x02019;s Republic of China</country></aff><aff id="aff0002"><label>2</label><institution>Center on Translational Neuroscience, School of Pharmacy, Minzu University of China</institution>, <addr-line>Beijing</addr-line>, <country>People&#x02019;s Republic of China</country></aff><aff id="aff0003"><label>3</label><institution>Institute of National Security, Minzu University of China</institution>, <addr-line>Beijing</addr-line>, <country>People&#x02019;s Republic of China</country></aff></contrib-group><author-notes><corresp id="an0001">Correspondence: Yong Cheng, <institution>Minzu Unviersity of China</institution>, <addr-line>27 South Zhongguancun Avenue</addr-line>, <addr-line>Beijing</addr-line>, <addr-line>100081</addr-line>, <country>People&#x02019;s Republic of China</country>, Email yongcheng@muc.edu.cn</corresp><corresp id="an0002">Guo-Jun Xie, <institution>The Third People&#x02019;s Hospital of Foshan</institution>, <addr-line>102 South Jinlan Road</addr-line>, <addr-line>Foshan</addr-line>, <addr-line>528041</addr-line>, <country>People&#x02019;s Republic of China</country>, Email xiegjfs@163.com</corresp><fn id="ft0001"><label>*</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date pub-type="epub"><day>29</day><month>8</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>18</volume><fpage>1885</fpage><lpage>1894</lpage><history><date date-type="received"><day>04</day><month>4</month><year>2022</year></date><date date-type="accepted"><day>17</day><month>8</month><year>2022</year></date></history><permissions><copyright-statement>&#x000a9; 2022 Li et al.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Li et al.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/3.0/</ali:license_ref><license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p></license></permissions><abstract><sec sec-type="intro" id="s2001"><title>Introduction</title><p>Major depression disorder is the most common diagnosed mental illnesses, and it bring a high social and economic burden. However, the current treatment for depression has limitations with side effects. Hence, there is an urgent need to search more effective treatment for major depressive disorder. Brain-derived neurotrophic factor (BDNF) is a neurotrophin that is vital to the survival, growth, and maintenance of neurons.</p></sec><sec id="s2002"><title>Methods</title><p>We administered BDNF into chronic unpredictable mild stress (CUMS)-induced depression mice and assessed the effects of intranasal delivery of BDNF in depression by the tail suspension test, forced swimming test, novelty suppressed feeding test, and open-field test.</p></sec><sec id="s2003"><title>Results</title><p>We find that the intranasal administration of BDNF reversed the depressive-like behaviors in CUMS mice as measured Further analyses suggested that BDNF treatment reduced pro-inflammatory cytokine (IL-6, TNF-&#x003b1;, iNOS and IL-1&#x003b2;) expressions in the hippocampus of CUMS mice. In addition, our results showed that BDNF markedly reduced oxidative stress in the hippocampus and blood of CUMS mice. Moreover, our data suggested that BDNF treatment increased neurogenesis in the hippocampus of CUMS mice.</p></sec><sec id="s2004"><title>Discussion</title><p>Taken together, our results for the first time demonstrated that intranasal delivery of BDNF protein exhibited anti-depressant-like effects in mice, and therefore may represent a new therapeutic strategy for major depressive disorder.</p></sec></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>depression</kwd><kwd>BDNF</kwd><kwd>neurogenesis</kwd><kwd>inflammatory cytokine</kwd><kwd>oxidative stress</kwd></kwd-group><counts><fig-count count="5"/><table-count count="1"/><ref-count count="36"/><page-count count="10"/></counts></article-meta></front><body><sec sec-type="intro" id="s0001"><title>Introduction</title><p>Major depressive disorder (MDD) is a highly prevalent psychiatric disorder characterized by depression mood, loss of interest and cognitive impairment, affecting more than 300 million people worldwide.<xref rid="cit0001" ref-type="bibr">1</xref>,<xref rid="cit0002" ref-type="bibr">2</xref> This disorder is easy to be misdiagnosed and with delayed treatment because of overlapping symptoms with other mental disorders.<xref rid="cit0003" ref-type="bibr">3</xref>,<xref rid="cit0004" ref-type="bibr">4</xref> It is predicted that MDD will be the leading cause of the global burden of disease by 2030.<xref rid="cit0005" ref-type="bibr">5</xref> Despite extensive research into the field and the emergence of a variety of available antidepressants, more than 30% of depressed patients fail to respond to antidepressant drug treatment.<xref rid="cit0006" ref-type="bibr">6</xref>,<xref rid="cit0007" ref-type="bibr">7</xref> Therefore, it is necessary to have a deeper understanding of the pathogenesis and molecular mechanism of MDD, which is of great significance for the development of new and effective treatments.</p><p>Brain-derived neurotrophic factor (BDNF) is a member of neurotrophin family that includes nerve growth factor (NGF), neurotrophin (NT)-3 and NT-4.<xref rid="cit0008" ref-type="bibr">8</xref> Among these neurotrophins, BDNF stands out for its high level of expression in the central nervous system (CNS) and its profound effects on development, morphology, and synaptic plasticity and function in the brain.<xref rid="cit0009" ref-type="bibr">9</xref>,<xref rid="cit0010" ref-type="bibr">10</xref> It has been widely studied in the past decade because of its association with a number of psychiatric disorders and their treatments, such as schizophrenia, intellectual disabilities, autism, and depression.<xref rid="cit0009" ref-type="bibr">9</xref> A growing body of evidence supports the BDNF was involved in the pathophysiology and/or therapeutic progression of MDD. For example, a large number of previous clinical studies have consistently reported significantly decreased serum and plasma BDNF levels in depressed patients and were inversely correlated with disease severity.<xref rid="cit0011" ref-type="bibr">11&#x02013;14</xref> Postmortem studies also support the role of BDNF in MDD, with a study showing reduced expression of BDNF in depressed suicidal patients and increased expression in patients treated with antidepressants.<xref rid="cit0015" ref-type="bibr">15</xref> Moreover, Shirayama et al found that injecting BDNF into hippocampus was sufficient to produce an antidepressant-like effect in behavioral models of depression.<xref rid="cit0016" ref-type="bibr">16</xref> However, the therapeutic potential of BDNF in MDD is still largely unknown.</p><p>Here we used a chronic stress-induced animal model of depression to determine whether intranasal delivery of BDNF can rescue depressive-like phenotypes in mice. The results showed that intranasal administration of BDNF ameliorated stress-induced depressive-like behaviors in mice, normalized peripheral and hippocampal oxidative factors levels, and reduced inflammatory factor levels in the hippocampus of stressed mice.</p></sec><sec id="s0002"><title>Materials and Methods</title><sec id="s0002-s2001"><title>Animals</title><p>C57BL/6 mice (male, 6-to 8-week-old) were purchased from Vital River Laboratory (Beijing, China). All mice were provided ad libitum access to a standard diet and drinking water, and raised at the temperature of 24 &#x000b1; 1&#x000b0;C and humidity of 50 &#x000b1; 1%) under a 14/10 h light/dark cycle. All animals were housed for 1 week to adapt to the environment. All animal procedures were approved by the Animal Care and Use Committee of the Minzu University of China, and the animal experiments were conducted in accordance with the National Institutes of Health Laboratory Animal Care and Use Guidelines (NIH Publication No. 80&#x02013;23).</p></sec><sec id="s0002-s2002"><title>Drug Administration</title><p>BDNF was purchased from Novoprotein (Cat. No: C076), and was dissolved in 0.01 M PBS. The mice were subjected to intranasal administration of BDNF at 40 ug/kg (CUMS+BDNF group) or equal volume of 0.01M PBS (control group and CUMS group) every day for 15 days.</p></sec><sec id="s0002-s2003"><title>CUMS Model Establishment and</title><p>The CUMS mouse model of depression was established according to our previously published paper,<xref rid="cit0017" ref-type="bibr">17</xref> and sources of stress included restraint stress and tail suspension. After three days of behavioral tests to confirm the establishment of depression model, BDNF or PBS was intranasally injected into the mice in different animal groups for 15 days. Then open-field test (OFT), forced swim test (FST), novelty suppressed feeding test (NSFT) and tail suspension test (TST) were used to measure the effects of BDNF on depressive-like behaviors in mice.</p></sec><sec id="s0002-s2004"><title>Behavioral Tests</title><p>The TST was performed following to previously published literature.<xref rid="cit0018" ref-type="bibr">18</xref> The OFT was performed as previously described with some modifications.<xref rid="cit0019" ref-type="bibr">19</xref> Briefly, mice were placed in an open-field apparatus (50 &#x000d7; 50&#x000d7;40 cm), and their movements were monitored for 15 min using a chart-couple device (CCD) camera. The image was captured with a computer using SMART V3.0 software. The distance moved and the time spent in the central area were calculated automatically.</p><p>The FST was performed according to previous literature with some modifications.<xref rid="cit0020" ref-type="bibr">20</xref> Briefly, mice were placed in a Plexiglas cylinder (15 cm diameter and 25 cm in height) containing water at a temperature of 23&#x02013;24 &#x000b0;C and a depth of 14 cm. The mice were forced to swim for 5 min and recorded with a video recorder.</p><p>The NSFT was also performed as described previously with some modifications.<xref rid="cit0021" ref-type="bibr">21</xref> Briefly, food-deprived mice were placed in an open field with a small amount of food in the center of the field, and latency to feed was measured under a time limit of 10 min. The timeline of CUMS model establishment and BDNF treatment was shown in <xref rid="f0001" ref-type="fig">Figure 1A</xref>, and the successful establishment of CUMS model was validated by the behavioral tests (<underline><ext-link xlink:href="https://www.dovepress.com/get_supplementary_file.php?f=369412.pdf" ext-link-type="uri">Supplementary Figure 1</ext-link></underline>)<fig position="float" id="f0001" fig-type="figure"><label>Figure 1</label><caption><p>Intranasal BDNF treatment ameliorated CUMS-induced depressive-like behaviors. (<bold>A</bold>) Schematic representation of experimental design for the CUMS-induced depression model. (<bold>B</bold>) BDNF restored the depressive-like behaviors in OFT. (<bold>C</bold>)BDNF restored the depressive-like behaviors in NSFT. (<bold>D</bold>)BDNF treated mice exhibited less depression-like behavior in TST. (<bold>E</bold>) BDNF treated mice showed less depressive-like behavior in FST. Data are presented as mean &#x000b1; S.E.M, n = 10 for control group, n = 10 for CUMS group, n = 9 for CUMS+BDNF group. *<italic toggle="yes">p</italic> &#x0003c; 0.05, **<italic toggle="yes">p</italic> &#x0003c; 0.01 and ***<italic toggle="yes">p</italic> &#x0003c; 0.001. One way ANOVA statistics: F <sub>a</sub> =47.90, F <sub>b</sub> = 14.77, F <sub>c</sub> =4.991, F <sub>d</sub> =4.723.</p></caption><graphic xlink:href="NDT-18-1885-g0001" content-type="print-only" position="float"/></fig></p></sec><sec id="s0002-s2005"><title>Oxidative Stress Marker Level/Activity Measurement</title><p>After the behavioral tests, the serum samples and hippocampal tissues from mice under various treatments were extracted with standard protocol. The malondialdehyde (MDA) level and (superoxide dismutase) SOD activity was measured by commercial available kits according to the manufacturer&#x02019;s instructions (Jiancheng Bioengineering Institute, Nanjing, China).</p></sec><sec id="s0002-s2006"><title>Quantitative Real-Time Polymerase Chain Reaction</title><p>Total RNA from hippocampal tissue was extracted with Trizol reagent. A PrimeScript RT reagent kit was used to synthesize first-strand cDNA. Then cDNAs were quantified by real-time polymerase chain reaction on LightCycler 96 (Roche). &#x003b2;-actin was used as a reference gene for analysis. Primers (sequences are shown in <xref rid="t0001" ref-type="table">Table 1</xref>) were synthesized by Sangon Biotech Co., Ltd (Shanghai, China). The relative mRNA expression levels were analyzed using the 2<sup>&#x02212;&#x00394;&#x00394;Ct</sup> method.<table-wrap position="float" id="t0001"><label>Table 1</label><caption><p>All Primer Sequences for qRT-PCR</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Genes</th><th colspan="2" align="center" rowspan="1">Primers (5&#x02019;-3&#x02019;)</th></tr></thead><tbody><tr><td rowspan="2" colspan="1">Il-1&#x003b2;</td><td rowspan="1" colspan="1">Forward</td><td rowspan="1" colspan="1">TGCCACCTTTTGACAGTGAT</td></tr><tr><td rowspan="1" colspan="1">Reverse</td><td rowspan="1" colspan="1">CCACAGCCACAATGAGTGAT</td></tr><tr><td rowspan="2" colspan="1">INOS</td><td rowspan="1" colspan="1">Forward</td><td rowspan="1" colspan="1">GGCGCTGTCATCGATTTCT</td></tr><tr><td rowspan="1" colspan="1">Reverse</td><td rowspan="1" colspan="1">GCCTTGTAGACACCTTGGTC</td></tr><tr><td rowspan="2" colspan="1">IL-6</td><td rowspan="1" colspan="1">Forward</td><td rowspan="1" colspan="1">CACAGAGGATACCACTCCCA</td></tr><tr><td rowspan="1" colspan="1">Reverse</td><td rowspan="1" colspan="1">GAATTGCCATTGCACAACTCT</td></tr><tr><td rowspan="2" colspan="1">TNF-&#x003b1;</td><td rowspan="1" colspan="1">Forward</td><td rowspan="1" colspan="1">GGCTTTCCGAATTCACTGGAG</td></tr><tr><td rowspan="1" colspan="1">Reverse</td><td rowspan="1" colspan="1">CCCCGGCCTTCCAAATAAA</td></tr><tr><td rowspan="2" colspan="1">&#x003b2;-Actin</td><td rowspan="1" colspan="1">Forward</td><td rowspan="1" colspan="1">AAGCCCTGGATGAAGAAACAG</td></tr><tr><td rowspan="1" colspan="1">Reverse</td><td rowspan="1" colspan="1">TGGGAACCAATCTCGTAGGTC</td></tr></tbody></table></table-wrap>
</p></sec><sec id="s0002-s2007"><title>Western Blotting</title><p>Western blotting was performed according to the standard protocol as described previously with modifications.<xref rid="cit0022" ref-type="bibr">22</xref> Hippocampal tissues of mice under various treatments were collected, and total proteins were extracted with RIPA buffer. The concentration of total protein was determined using a BCA protein quantification kit and. 30 &#x003bc;g of protein from each sample was separated on SDS-PAGE gel, then transferred to NC membrane. The NC membrane was blocked with blocking solution for 1 h and then incubated with the primary antibody overnight at 4 &#x000b0;C. After washing with TBST three times, the membrane was incubated with the HRP-conjugated secondary antibody for 1 h at room temperature. After washing the membrane, the signal was visualized by a chemiluminescence imager (Beijing Yuan Ping Hao Biotechnology Co. Ltd., Beijing, China). Data were analyzed using Image J software. The primary antibodies used in this study were anti-IL-1&#x003b2; (#254360, Abcam, 1:1000), anti-NLRP3 (AG-20B-0014, Adipogen, 1:1000), anti-TNF-&#x003b1; (#11948S, Cell signaling Technology, 1:1000) and anti- &#x003b2;-Actin (#4967S, Cell signaling Technology, 1:1000).</p></sec><sec id="s0002-s2008"><title>Statistical Analysis</title><p>All data are presented as means &#x000b1; SEM (standard error of the mean). Statistical significance was analyzed by one-way ANOVA followed by multiple comparison tests with GraphPad Prism 8, p &#x0003c; 0.05 was considered statistically significant.</p></sec></sec><sec id="s0003"><title>Results</title><sec id="s0003-s2001"><title>Intranasal BDNF Administration Ameliorates Depression-Like Behaviors in CUMS Model Mice</title><p>To investigate the effects of BDNF on CUMS-induced depressive-like behaviors in mice, we performed several behavioral test including OFT, NSFT, FST and TST. The OFT showed that the total distance traveled in CUMS model mice was significantly reduced comparted to non-stressed controls (<xref rid="f0001" ref-type="fig">Figure 1B</xref>, <italic toggle="yes">p</italic> &#x0003c; 0.001). However, treatment with BDNF significantly increased the traveled distance (<xref rid="f0001" ref-type="fig">Figure 1B</xref>, <italic toggle="yes">p</italic> &#x0003c; 0.001), which reflected BDNF markedly improved the CUMS-induced reduction of locomotor activity in mice. Moreover, the NSFT demonstrated that compared with the control mice, the latency to feed was significantly increased in the CUMS mice (<xref rid="f0001" ref-type="fig">Figure 1C</xref>, <italic toggle="yes">p</italic> &#x0003c; 0.001), while intranasal delivery of BDNF significantly reversed this effect (<xref rid="f0001" ref-type="fig">Figure 1C</xref>, <italic toggle="yes">p</italic> &#x0003c; 0.05). Additionally, the desperate behaviors in mice were assessed by the immobility time in the TST and FST. The results showed that durations of immobility were significantly longer in the CUMS mice than in controls, whereas BDNF administration remarkably reduced the immobility time in the stressed mice (<xref rid="f0001" ref-type="fig">Figure 1D</xref> and <xref rid="f0001" ref-type="fig">E</xref>). Taken together, these results shown that intranasal administration of BDNF ameliorates CUMS-induced depressive-like behaviors in mice.</p></sec><sec id="s0003-s2002"><title>Intranasal Delivery of BDNF Reduced Oxidative Stress in CUMS Mice</title><p>Next, we analyzed oxidative stress marker level or activity in each group of mice to assess the effects of BDNF on CUMS-induced oxidative stress damage in mice. The result indicated that, compared to the control group, CUMS model mice had significantly increased serum MDA level (<xref rid="f0002" ref-type="fig">Figure 2A</xref>, <italic toggle="yes">p</italic> &#x0003c; 0.05) and reduced SOD activity (<xref rid="f0002" ref-type="fig">Figure 2B</xref>, <italic toggle="yes">p</italic> &#x0003c; 0.05). However, BDNF treatment markedly reduced MDA level in CUMS mice, but did not have significant effect on SOD activity, as shown in <xref rid="f0002" ref-type="fig">Figure 2A</xref> and <xref rid="f0002" ref-type="fig">B</xref>. We also found that CUMS mice had significantly increased MAD level (<xref rid="f0002" ref-type="fig">Figure 2C</xref>, <italic toggle="yes">p</italic> &#x0003c; 0.001) and decreased SOD activity (<xref rid="f0002" ref-type="fig">Figure 2D</xref>, <italic toggle="yes">p</italic> &#x0003c; 0.001) in the hippocampus when compared with controls, and these effects were abolished by intranasal administration of BDNF in the CUMS mice (<xref rid="f0002" ref-type="fig">Figure 2C</xref> and <xref rid="f0002" ref-type="fig">D</xref>).<fig position="float" id="f0002" fig-type="figure"><label>Figure 2</label><caption><p>Intranasal BDNF treatment reduced oxidative stress in CUMS model mic. The serum MDA levels (<bold>A</bold>) and SOD activities (<bold>B</bold>) in mice under various treatments. The hippocampal MDA levels (<bold>C</bold>) and SOD (<bold>D</bold>) activities in mice under various treatments. Values are expressed as the mean &#x000b1; SEM, n = 8 for control group, n = 8 for CUMS group, n = 7 for CUMS+BDNF group. *p &#x0003c; 0.05, **p &#x0003c; 0.01 and ***p &#x0003c; 0.001. One way ANOVA statistics: F <sub>a</sub> =6.943, F <sub>b</sub> = 2.401, F <sub>c</sub> =13.36, F <sub>d</sub> =54.60.</p></caption><graphic xlink:href="NDT-18-1885-g0002" content-type="print-only" position="float"/></fig></p></sec><sec id="s0003-s2003"><title>Intranasal Delivery of BDNF Inhibited Inflammatory Response in the Hippocampus of CUMS Mice</title><p>To further explore potential mechanism underlying the anti-depressant effects of BDNF, we next examined several of pro-inflammatory cytokine mRNA expression in the hippocampus. As demonstrated in <xref rid="f0003" ref-type="fig">Figure 3</xref>, the results revealed that the mRNA levels of interleukin (IL)-1&#x003b2;, IL-6, iNOS, and tumor necrosis factor (TNF)-&#x003b1; were significantly increased in the CUMS mice when compared with control mice. However, BDNF treatment significantly reduced TNF-&#x003b1;, IL-1&#x003b2;, and IL-6 mRNA levels in the hippocampus of CUSM mice (<xref rid="f0003" ref-type="fig">Figure 3</xref>).<fig position="float" id="f0003" fig-type="figure"><label>Figure 3</label><caption><p>Intranasal BDNF treatment reduced inflammatory-associated gene expressions in the hippocampus of CUMS model mice. The hippocampal mRNA expression levels of IL-1&#x003b2; (<bold>A</bold>), TNF-&#x003b1; (<bold>B</bold>), iNOS (<bold>C</bold>) and IL-6 (<bold>D</bold>) in mice under various treatments. Data are presented as mean &#x000b1; S.E.M, n = 3, *<italic toggle="yes">p</italic> &#x0003c; 0.05 and **<italic toggle="yes">p</italic> &#x0003c; 0.01. One way ANOVA statistics: F <sub>a</sub> =25.20, F <sub>b</sub> = 25.93, F <sub>c</sub> =5.338, F <sub>d</sub> =12.56.</p></caption><graphic xlink:href="NDT-18-1885-g0003" content-type="print-only" position="float"/></fig></p><p>Additionally, the Western blot results showed that IL-1&#x003b2; and TNF-&#x003b1; protein were significantly up-regulated in the hippocampus of CUMS model mice relative to the control mice, whereas BDNF treatment significantly reduced IL-1&#x003b2; and TNF-&#x003b1; protein expression in the hippocampus of the model mice, as shown in the <xref rid="f0004" ref-type="fig">Figure 4</xref>. Interestingly, our results also showed that BDNF significantly inhibited stress-induced up-regulation of NLRP3 protein expression in the hippocampus (<xref rid="f0004" ref-type="fig">Figure 4</xref>). These results therefore suggested the involvement of anti-inflammatory response on the intranasal BDNF induced-antidepressant-like effects.<fig position="float" id="f0004" fig-type="figure"><label>Figure 4</label><caption><p>Intranasal BDNF treatment reduced inflammatory-associated protein levels in the hippocampus of CUMS model mice. (<bold>A</bold>) Representative images showing BDNF reduced NLRP3, IL-1&#x003b2; and TNF-&#x003b1; protein levels in the hippocampus of CUMS mice as measured by Western blot.Quantifications of the relative band densities of IL-1&#x003b2; (<bold>B</bold>), NLRP3 (<bold>C</bold>), and TNF-&#x003b1; (<bold>D</bold>) in the hippocampus of mice under various treatments. Data are presented as mean &#x000b1; S.E.M, n = 3. *<italic toggle="yes">p</italic> &#x0003c; 0.05 and **<italic toggle="yes">p</italic> &#x0003c; 0.01. One way ANOVA statistics: F<sub>b</sub> =16.74, F <sub>c</sub> = 18.12, F <sub>d</sub> = 6.832.</p></caption><graphic xlink:href="NDT-18-1885-g0004" content-type="print-only" position="float"/></fig></p></sec><sec id="s0003-s2004"><title>BDNF Restored Hippocampus Neurogenesis in the CUMS Mice</title><p>We then used the immunofluorescence analysis to evaluate the effect of BDNF on hippocampal neurogenesis, and this protocol was followed by our previously published literature.<xref rid="cit0021" ref-type="bibr">21</xref> We found that CUMS exposure markedly reduced doublecortin (a marker of neurogenesis) positive cells in the dentate gyrus of hippocampus, and the reduction was recovered after intranasal BDNF treatment (<xref rid="f0005" ref-type="fig">Figure 5</xref>), suggesting that intranasal administration of BDNF may exert antidepressant effect by increasing neurogenesis.<fig position="float" id="f0005" fig-type="figure"><label>Figure 5</label><caption><p>Effect of BDNF treatment on neurogenesis in the hippocampus. (<bold>A</bold>) Confocal photomicrographs of doublecortin-immunostained immature neurons in the dentate gyrus of mice under various treatments. (<bold>B</bold>) Quantification of doublecortin-positive cells in the dentate gyrus of mice under various treatments. Data are presented as mean &#x000b1; S.E.M, n = 4. ***<italic toggle="yes">p</italic> &#x0003c; 0.001. One way ANOVA statistics: F <sub>a</sub> = 42.39.</p></caption><graphic xlink:href="NDT-18-1885-g0005" content-type="print-only" position="float"/></fig></p></sec></sec><sec id="s0004"><title>Discussion</title><p>In the present study, we found that intranasal BDNF administration produces antidepressant-like behavioral responses in stress-induced depression in mice. These effects were similar to the actions of subcutaneous BDNF administration in an animal model of depression,<xref rid="cit0023" ref-type="bibr">23</xref> as well as centrally administered BDNF which included the midbrain,<xref rid="cit0016" ref-type="bibr">16</xref> hippocampus<xref rid="cit0021" ref-type="bibr">21</xref> and lateral ventricles.<xref rid="cit0024" ref-type="bibr">24</xref> Preclinical studies have also suggested reduced BDNF levels in animal models of depression, both in central and peripheral.<xref rid="cit0025" ref-type="bibr">25</xref>,<xref rid="cit0026" ref-type="bibr">26</xref> Although the molecular mechanisms underlying the link between stress and depression is still largely unknown, these preclinical studies have shown that chronic stress induced depression-like symptoms are associated with decreased levels of BDNF. Additionally, neurotrophic factors have been demonstrated to control depressive-like behaviors in rodents through hippocampus, these include BDNF<xref rid="cit0027" ref-type="bibr">27</xref> and neurotrophic factor-&#x003b1;1.<xref rid="cit0028" ref-type="bibr">28</xref> Furthermore, there is a well-established body of clinical evidence demonstrated that the levels of BDNF in serum and plasma were reduced in MDD patients.<xref rid="cit0029" ref-type="bibr">29</xref>,<xref rid="cit0030" ref-type="bibr">30</xref> Interestingly, antidepressants have been shown to increase BDNF levels in the peripheral blood of MDD patients.<xref rid="cit0031" ref-type="bibr">31</xref> Therefore, our results presented in this study together with previous findings provide strong evidence to support the hypothesis that BDNF is involved in the pathogenesis of depression, and intranasal delivery of BNDF may represent a novel strategy for treatment of depression.</p><p>Although the down-stream signaling pathway alterations caused by BDNF deficiency are not fully understood, the abnormal BDNF level-induced pathological conditions may be due to the chronic inflammatory state of the brain in certain diseases, as evidence from recent studies reporting that peripheral immune challenge caused BDNF deficiency resulted in an abnormal neuroinflammation response, which then lead to the development of inflammation-induced anhedonia in mice.<xref rid="cit0032" ref-type="bibr">32</xref>,<xref rid="cit0033" ref-type="bibr">33</xref> In addition, Gibney et al have also found increased expression of IL-1&#x003b2;, IL-6, and TNF-&#x003b1; and reduced expression of BDNF genes in depressive-like rats 6 h after an inflammatory challenge.<xref rid="cit0034" ref-type="bibr">34</xref> Consistently, our results showed that the expressions of pro-inflammatory cytokines including IL-1&#x003b2;, IL-6, and TNF-&#x003b1; levels were significantly elevated in the hippocampal tissues of CUMS-induced depressed mice, whereas intranasal delivery of BDNF significantly improved CUMS-induced depression-like behaviors and reduced these pro-inflammatory cytokine expressions in the hippocampus. Based on these findings, it is reasonable to speculate that long-term exposure to stress caused decreased levels of BDNF and neuroinflammation in the body and ultimately contributes to the pathophysiology of MDD.<xref rid="cit0035" ref-type="bibr">35</xref>,<xref rid="cit0036" ref-type="bibr">36</xref> However, further research is needed to further understand the role interactions between neurotrophic factors and neuroinflammation in the pathogenesis of depression.</p><p>In conclusion, we demonstrated that intranasal administration of BDNF rescued depressive-like behaviors in a CUMS-induced mice model of depression. The therapeutic effects of BDNF were accompanied by restorations of neuroinflammation, oxidative stress and hippocampal neurogenesis in CUMS model mice. Therefore, future studies are warranted to explore the potential of intranasal BDNF delivery as a therapeutic target to treat MDD.</p></sec></body><back><ack><title>Acknowledgments</title><p>This study was supported by the Natural Science Foundation of Guangdong Province (2114050002827), the National Natural Science Foundation of China (82071676), the High-Level Hospital Development Program for Foshan &#x0201c;Climbing&#x0201d; Project, and Foshan Science and technology innovation project (2020001005608).</p></ack><sec id="s0005"><title>Data Sharing Statement</title><p>All data are contained within the manuscript.</p></sec><sec id="s0006"><title>Author Contributions</title><p>All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.</p></sec><sec sec-type="COI-statement" id="s0007"><title>Disclosure</title><p>The authors declare that there are no conflicts of interest.</p></sec><ref-list><title>References</title><ref id="cit0001"><label>1.</label><mixed-citation publication-type="journal"><string-name><surname>Otte</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Gold</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Penninx</surname>
<given-names>BW</given-names></string-name>, et al. <article-title>Major depressive disorder</article-title>. <source><italic toggle="yes">Nat Rev Dis Primers</italic></source>. <year>2016</year>;<volume>2</volume>(<issue>1</issue>):<fpage>16065</fpage>. doi:<pub-id pub-id-type="doi">10.1038/nrdp.2016.65</pub-id><pub-id pub-id-type="pmid">27629598</pub-id></mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="journal"><string-name><surname>Kessler</surname>
<given-names>RC</given-names></string-name>, <string-name><surname>Bromet</surname>
<given-names>EJ</given-names></string-name>. <article-title>The epidemiology of depression across cultures</article-title>. <source><italic toggle="yes">Annu Rev Public Health</italic></source>. <year>2013</year>;<volume>34</volume>:<fpage>119</fpage>&#x02013;<lpage>138</lpage>. doi:<pub-id pub-id-type="doi">10.1146/annurev-publhealth-031912-114409</pub-id><pub-id pub-id-type="pmid">23514317</pub-id></mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Moffitt</surname>
<given-names>TE</given-names></string-name>, <string-name><surname>Caspi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Taylor</surname>
<given-names>A</given-names></string-name>, et al. <article-title>How common are common mental disorders? Evidence that lifetime prevalence rates are doubled by prospective versus retrospective ascertainment</article-title>. <source><italic toggle="yes">Psychol Med</italic></source>. <year>2010</year>;<volume>40</volume>(<issue>6</issue>):<fpage>899</fpage>&#x02013;<lpage>909</lpage>. doi:<pub-id pub-id-type="doi">10.1017/S0033291709991036</pub-id><pub-id pub-id-type="pmid">19719899</pub-id></mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="journal"><string-name><surname>Zhou</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Lan</surname>
<given-names>X</given-names></string-name>, et al. <article-title>Polyunsaturated fatty acids metabolism, purine metabolism and inosine as potential independent diagnostic biomarkers for major depressive disorder in children and adolescents</article-title>. <source><italic toggle="yes">Mol Psychiatry</italic></source>. <year>2019</year>;<volume>24</volume>(<issue>10</issue>):<fpage>1478</fpage>&#x02013;<lpage>1488</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41380-018-0047-z</pub-id><pub-id pub-id-type="pmid">29679072</pub-id></mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="journal"><string-name><surname>Song</surname>
<given-names>AQ</given-names></string-name>, <string-name><surname>Gao</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Fan</surname>
<given-names>-J-J</given-names></string-name>, et al. <article-title>NLRP1 inflammasome contributes to chronic stress-induced depressive-like behaviors in mice</article-title>. <source><italic toggle="yes">J Neuroinflammation</italic></source>. <year>2020</year>;<volume>17</volume>(<issue>1</issue>):<fpage>178</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12974-020-01848-8</pub-id><pub-id pub-id-type="pmid">32513185</pub-id></mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="journal"><string-name><surname>Amsterdam</surname>
<given-names>JD</given-names></string-name>, <string-name><surname>Maislin</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Potter</surname>
<given-names>L</given-names></string-name>. <article-title>Fluoxetine efficacy in treatment resistant depression</article-title>. <source><italic toggle="yes">Prog Neuropsychopharmacol Biol Psychiatry</italic></source>. <year>1994</year>;<volume>18</volume>(<issue>2</issue>):<fpage>243</fpage>&#x02013;<lpage>261</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0278-5846(94)90057-4</pub-id><pub-id pub-id-type="pmid">8208976</pub-id></mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Hamon</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Blier</surname>
<given-names>P</given-names></string-name>. <article-title>Monoamine neurocircuitry in depression and strategies for new treatments</article-title>. <source><italic toggle="yes">Prog Neuropsychopharmacol Biol Psychiatry</italic></source>. <year>2013</year>;<volume>45</volume>:<fpage>54</fpage>&#x02013;<lpage>63</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pnpbp.2013.04.009</pub-id><pub-id pub-id-type="pmid">23602950</pub-id></mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="journal"><string-name><surname>Liu</surname>
<given-names>SH</given-names></string-name>, <string-name><surname>Shi</surname>
<given-names>XJ</given-names></string-name>, <string-name><surname>Fan</surname>
<given-names>FC</given-names></string-name>, <string-name><surname>Cheng</surname>
<given-names>Y</given-names></string-name>. <article-title>Peripheral blood neurotrophic factor levels in children with autism spectrum disorder: a meta-analysis</article-title>. <source><italic toggle="yes">Sci Rep</italic></source>. <year>2021</year>;<volume>11</volume>:<fpage>15</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-020-79080-w</pub-id><pub-id pub-id-type="pmid">33420109</pub-id></mixed-citation></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="journal"><string-name><surname>Autry</surname>
<given-names>AE</given-names></string-name>, <string-name><surname>Monteggia</surname>
<given-names>LM</given-names></string-name>. <article-title>Brain-derived neurotrophic factor and neuropsychiatric disorders</article-title>. <source><italic toggle="yes">Pharmacol Rev</italic></source>. <year>2012</year>;<volume>64</volume>:<fpage>238</fpage>&#x02013;<lpage>258</lpage>. doi:<pub-id pub-id-type="doi">10.1124/pr.111.005108</pub-id><pub-id pub-id-type="pmid">22407616</pub-id></mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Lu</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Nagappan</surname>
<given-names>G</given-names></string-name>, <string-name><surname>BDNF</surname>
<given-names>LY</given-names></string-name>. <article-title>and synaptic plasticity, cognitive function, and dysfunction</article-title>. <source><italic toggle="yes">Handb Exp Pharmacol</italic></source>. <year>2014</year>;<volume>220</volume>:<fpage>223</fpage>&#x02013;<lpage>250</lpage>.<pub-id pub-id-type="pmid">24668475</pub-id></mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>Karege</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Perret</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Bondolfi</surname>
<given-names>G</given-names></string-name>, et al. <article-title>Decreased serum brain-derived neurotrophic factor levels in major depressed patients</article-title>. <source><italic toggle="yes">Psychiatry Res</italic></source>. <year>2002</year>;<volume>109</volume>(<issue>2</issue>):<fpage>143</fpage>&#x02013;<lpage>148</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0165-1781(02)00005-7</pub-id><pub-id pub-id-type="pmid">11927139</pub-id></mixed-citation></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="journal"><string-name><surname>Aydemir</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Yalcin</surname>
<given-names>ES</given-names></string-name>, <string-name><surname>Aksaray</surname>
<given-names>S</given-names></string-name>, et al. <article-title>Brain-derived neurotrophic factor (BDNF) changes in the serum of depressed women</article-title>. <source><italic toggle="yes">Prog Neuropsychopharmacol Biol Psychiatry</italic></source>. <year>2006</year>;<volume>30</volume>(<issue>7</issue>):<fpage>1256</fpage>&#x02013;<lpage>1260</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pnpbp.2006.03.025</pub-id><pub-id pub-id-type="pmid">16647794</pub-id></mixed-citation></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Kim</surname>
<given-names>Y-K</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>H-P</given-names></string-name>, <string-name><surname>Won</surname>
<given-names>S-D</given-names></string-name>, et al. <article-title>Low plasma BDNF is associated with suicidal behavior in major depression</article-title>. <source><italic toggle="yes">Prog Neuropsychopharmacol Biol Psychiatry</italic></source>. <year>2007</year>;<volume>31</volume>(<issue>1</issue>):<fpage>78</fpage>&#x02013;<lpage>85</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pnpbp.2006.06.024</pub-id><pub-id pub-id-type="pmid">16904252</pub-id></mixed-citation></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>Lee</surname>
<given-names>BH</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>SH</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>YK</given-names></string-name>. <article-title>Decreased plasma BDNF level in depressive patients</article-title>. <source><italic toggle="yes">J Affect Disord</italic></source>. <year>2007</year>;<volume>101</volume>:<fpage>239</fpage>&#x02013;<lpage>244</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jad.2006.11.005</pub-id><pub-id pub-id-type="pmid">17173978</pub-id></mixed-citation></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="journal"><string-name><surname>Chen</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Dowlatshahi</surname>
<given-names>D</given-names></string-name>, <string-name><surname>MacQueen</surname>
<given-names>GM</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>JF</given-names></string-name>, <string-name><surname>Young</surname>
<given-names>LT</given-names></string-name>. <article-title>Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication</article-title>. <source><italic toggle="yes">Biol Psychiatry</italic></source>. <year>2001</year>;<volume>50</volume>:<fpage>260</fpage>&#x02013;<lpage>265</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0006-3223(01)01083-6</pub-id><pub-id pub-id-type="pmid">11522260</pub-id></mixed-citation></ref><ref id="cit0016"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>Shirayama</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>AC</given-names></string-name>, <string-name><surname>Nakagawa</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Russell</surname>
<given-names>DS</given-names></string-name>, <string-name><surname>Duman</surname>
<given-names>RS</given-names></string-name>. <article-title>Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression</article-title>. <source><italic toggle="yes">J Neurosci</italic></source>. <year>2002</year>;<volume>22</volume>:<fpage>3251</fpage>&#x02013;<lpage>3261</lpage>. doi:<pub-id pub-id-type="doi">10.1523/JNEUROSCI.22-08-03251.2002</pub-id><pub-id pub-id-type="pmid">11943826</pub-id></mixed-citation></ref><ref id="cit0017"><label>17.</label><mixed-citation publication-type="journal"><string-name><surname>Wang</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>-X-X</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>X</given-names></string-name>, et al. <article-title>Antidepressant-Like Effects of Low- and High-Molecular Weight FGF-2 on Chronic Unpredictable Mild Stress Mice</article-title>. <source><italic toggle="yes">Front Mol Neurosci</italic></source>. <year>2018</year>;<volume>11</volume>:<fpage>377</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fnmol.2018.00377</pub-id><pub-id pub-id-type="pmid">30369869</pub-id></mixed-citation></ref><ref id="cit0018"><label>18.</label><mixed-citation publication-type="journal"><string-name><surname>Du</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Tan</surname>
<given-names>W-L</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>L</given-names></string-name>, et al. <article-title>Exosome Transplantation From Patients With Schizophrenia Causes Schizophrenia-Relevant Behaviors in Mice: an Integrative Multi-omics Data Analysis</article-title>. <source><italic toggle="yes">Schizophr Bull</italic></source>. <year>2021</year>;<volume>47</volume>(<issue>5</issue>):<fpage>1288</fpage>&#x02013;<lpage>1299</lpage>. doi:<pub-id pub-id-type="doi">10.1093/schbul/sbab039</pub-id><pub-id pub-id-type="pmid">33837780</pub-id></mixed-citation></ref><ref id="cit0019"><label>19.</label><mixed-citation publication-type="journal"><string-name><surname>Jiang</surname>
<given-names>CY</given-names></string-name>, <string-name><surname>Qin</surname>
<given-names>XY</given-names></string-name>, <string-name><surname>Yuan</surname>
<given-names>MM</given-names></string-name>, <string-name><surname>Lu</surname>
<given-names>GJ</given-names></string-name>, <string-name><surname>Cheng</surname>
<given-names>Y</given-names></string-name>. <article-title>2,3,5,4&#x02019;-Tetrahydroxystilbene-2-O-beta-D-glucoside Reverses Stress-Induced Depression via Inflammatory and Oxidative Stress Pathways</article-title>. <source><italic toggle="yes">Oxid Med Cell Longev</italic></source>. <year>2018</year>;<volume>2018</volume>:<fpage>9501427</fpage>. doi:<pub-id pub-id-type="doi">10.1155/2018/9501427</pub-id><pub-id pub-id-type="pmid">30327715</pub-id></mixed-citation></ref><ref id="cit0020"><label>20.</label><mixed-citation publication-type="journal"><string-name><surname>Kim</surname>
<given-names>KS</given-names></string-name>, <string-name><surname>Han</surname>
<given-names>PL</given-names></string-name>. <article-title>Optimization of chronic stress paradigms using anxiety- and depression-like behavioral parameters</article-title>. <source><italic toggle="yes">J Neurosci Res</italic></source>. <year>2006</year>;<volume>83</volume>:<fpage>497</fpage>&#x02013;<lpage>507</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jnr.20754</pub-id><pub-id pub-id-type="pmid">16416425</pub-id></mixed-citation></ref><ref id="cit0021"><label>21.</label><mixed-citation publication-type="journal"><string-name><surname>Wei</surname>
<given-names>ZX</given-names></string-name>, <string-name><surname>Xie</surname>
<given-names>G-J</given-names></string-name>, <string-name><surname>Mao</surname>
<given-names>X</given-names></string-name>, et al. <article-title>Exosomes from patients with major depression cause depressive-like behaviors in mice with involvement of miR-139-5p-regulated neurogenesis</article-title>. <source><italic toggle="yes">Neuropsychopharmacology</italic></source>. <year>2020</year>;<volume>45</volume>(<issue>6</issue>):<fpage>1050</fpage>&#x02013;<lpage>1058</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41386-020-0622-2</pub-id><pub-id pub-id-type="pmid">31986519</pub-id></mixed-citation></ref><ref id="cit0022"><label>22.</label><mixed-citation publication-type="journal"><string-name><surname>Chen</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Cheng</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Kardami</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Loh</surname>
<given-names>YP</given-names></string-name>. <article-title>Low and High Molecular Weight FGF-2 Have Differential Effects on Astrocyte Proliferation, but Are Both Protective Against Abeta-Induced Cytotoxicity</article-title>. <source><italic toggle="yes">Front Mol Neurosci</italic></source>. <year>2019</year>;<volume>12</volume>:<fpage>328</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fnmol.2019.00328</pub-id><pub-id pub-id-type="pmid">32038161</pub-id></mixed-citation></ref><ref id="cit0023"><label>23.</label><mixed-citation publication-type="journal"><string-name><surname>Schmidt</surname>
<given-names>HD</given-names></string-name>, <string-name><surname>Duman</surname>
<given-names>RS</given-names></string-name>. <article-title>Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models</article-title>. <source><italic toggle="yes">Neuropsychopharmacology</italic></source>. <year>2010</year>;<volume>35</volume>(<issue>12</issue>):<fpage>2378</fpage>&#x02013;<lpage>2391</lpage>. doi:<pub-id pub-id-type="doi">10.1038/npp.2010.114</pub-id><pub-id pub-id-type="pmid">20686454</pub-id></mixed-citation></ref><ref id="cit0024"><label>24.</label><mixed-citation publication-type="journal"><string-name><surname>Hoshaw</surname>
<given-names>BA</given-names></string-name>, <string-name><surname>Malberg</surname>
<given-names>JE</given-names></string-name>, <string-name><surname>Lucki</surname>
<given-names>I</given-names></string-name>. <article-title>Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects</article-title>. <source><italic toggle="yes">Brain Res</italic></source>. <year>2005</year>;<volume>1037</volume>(<issue>1&#x02013;2</issue>):<fpage>204</fpage>&#x02013;<lpage>208</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.brainres.2005.01.007</pub-id><pub-id pub-id-type="pmid">15777771</pub-id></mixed-citation></ref><ref id="cit0025"><label>25.</label><mixed-citation publication-type="journal"><string-name><surname>Arosio</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Guerini</surname>
<given-names>FR</given-names></string-name>, <string-name><surname>Voshaar</surname>
<given-names>RCO</given-names></string-name>, <string-name><surname>Aprahamian</surname>
<given-names>I</given-names></string-name>. <article-title>Blood Brain-Derived Neurotrophic Factor (BDNF) and Major Depression: do We Have a Translational Perspective?</article-title>
<source><italic toggle="yes">Front Behav Neurosci</italic></source>. <year>2021</year>;<volume>15</volume>:<fpage>626906</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fnbeh.2021.626906</pub-id><pub-id pub-id-type="pmid">33643008</pub-id></mixed-citation></ref><ref id="cit0026"><label>26.</label><mixed-citation publication-type="journal"><string-name><surname>Youssef</surname>
<given-names>MM</given-names></string-name>, <string-name><surname>Underwood</surname>
<given-names>MD</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>-Y-Y</given-names></string-name>, et al. <article-title>Association of BDNF Val66Met Polymorphism and Brain BDNF Levels with Major Depression and Suicide</article-title>. <source><italic toggle="yes">Int J Neuropsychopharmacol</italic></source>. <year>2018</year>;<volume>21</volume>(<issue>6</issue>):<fpage>528</fpage>&#x02013;<lpage>538</lpage>. doi:<pub-id pub-id-type="doi">10.1093/ijnp/pyy008</pub-id><pub-id pub-id-type="pmid">29432620</pub-id></mixed-citation></ref><ref id="cit0027"><label>27.</label><mixed-citation publication-type="journal"><string-name><surname>Liu</surname>
<given-names>J-H</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>Z-L</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>Y-S</given-names></string-name>, et al. <article-title>Astrocytic GABAB Receptors in Mouse Hippocampus Control Responses to Behavioral Challenges through Astrocytic BDNF</article-title>. <source><italic toggle="yes">Neurosci Bull</italic></source>. <year>2020</year>;<volume>36</volume>(<issue>7</issue>):<fpage>705</fpage>&#x02013;<lpage>718</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12264-020-00474-x</pub-id><pub-id pub-id-type="pmid">32166647</pub-id></mixed-citation></ref><ref id="cit0028"><label>28.</label><mixed-citation publication-type="journal"><string-name><surname>Cheng</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Rodriguiz</surname>
<given-names>RM</given-names></string-name>, <string-name><surname>Murthy</surname>
<given-names>SRK</given-names></string-name>, et al. <article-title>Neurotrophic factor-alpha1 prevents stress-induced depression through enhancement of neurogenesis and is activated by rosiglitazone</article-title>. <source><italic toggle="yes">Mol Psychiatry</italic></source>. <year>2015</year>;<volume>20</volume>(<issue>6</issue>):<fpage>744</fpage>&#x02013;<lpage>754</lpage>. doi:<pub-id pub-id-type="doi">10.1038/mp.2014.136</pub-id><pub-id pub-id-type="pmid">25330741</pub-id></mixed-citation></ref><ref id="cit0029"><label>29.</label><mixed-citation publication-type="journal"><string-name><surname>Phillips</surname>
<given-names>C</given-names></string-name>. <article-title>Brain-Derived Neurotrophic Factor, Depression, and Physical Activity: making the Neuroplastic Connection</article-title>. <source><italic toggle="yes">Neural Plast</italic></source>. <year>2017</year>;<volume>2017</volume>:<fpage>7260130</fpage>. doi:<pub-id pub-id-type="doi">10.1155/2017/7260130</pub-id><pub-id pub-id-type="pmid">28928987</pub-id></mixed-citation></ref><ref id="cit0030"><label>30.</label><mixed-citation publication-type="journal"><string-name><surname>Chen</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>XS</given-names></string-name>, <string-name><surname>Zheng</surname>
<given-names>GE</given-names></string-name>, <string-name><surname>Xie</surname>
<given-names>GJ</given-names></string-name>, <string-name><surname>Cheng</surname>
<given-names>Y</given-names></string-name>. <article-title>Peripheral blood BDNF-TrkB signaling in first-episode, drug-free patients with major depressive disorder and schizophrenia</article-title>. <source><italic toggle="yes">Neurosci Lett</italic></source>. <year>2020</year>;<volume>714</volume>:<fpage>134618</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neulet.2019.134618</pub-id><pub-id pub-id-type="pmid">31711978</pub-id></mixed-citation></ref><ref id="cit0031"><label>31.</label><mixed-citation publication-type="journal"><string-name><surname>Chiou</surname>
<given-names>YJ</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>TL</given-names></string-name>. <article-title>Accuracy of brain-derived neurotrophic factor levels for differentiating between Taiwanese patients with major depressive disorder or schizophrenia and healthy controls</article-title>. <source><italic toggle="yes">PLoS One</italic></source>. <year>2019</year>;<volume>14</volume>:<fpage>e0212373</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0212373</pub-id><pub-id pub-id-type="pmid">30794585</pub-id></mixed-citation></ref><ref id="cit0032"><label>32.</label><mixed-citation publication-type="journal"><string-name><surname>Lima Giacobbo</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Doorduin</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Klein</surname>
<given-names>HC</given-names></string-name>, et al. <article-title>Brain-Derived Neurotrophic Factor in Brain Disorders: focus on Neuroinflammation</article-title>. <source><italic toggle="yes">Mol Neurobiol</italic></source>. <year>2019</year>;<volume>56</volume>(<issue>5</issue>):<fpage>3295</fpage>&#x02013;<lpage>3312</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12035-018-1283-6</pub-id><pub-id pub-id-type="pmid">30117106</pub-id></mixed-citation></ref><ref id="cit0033"><label>33.</label><mixed-citation publication-type="journal"><string-name><surname>Parrott</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Porter</surname>
<given-names>GA</given-names></string-name>, <string-name><surname>Redus</surname>
<given-names>L</given-names></string-name>, <string-name><surname>O&#x02019;Connor</surname>
<given-names>JC</given-names></string-name>. <article-title>Brain derived neurotrophic factor deficiency exacerbates inflammation-induced anhedonia in mice</article-title>. <source><italic toggle="yes">Psychoneuroendocrinology</italic></source>. <year>2021</year>;<volume>134</volume>:<fpage>105404</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.psyneuen.2021.105404</pub-id><pub-id pub-id-type="pmid">34601342</pub-id></mixed-citation></ref><ref id="cit0034"><label>34.</label><mixed-citation publication-type="journal"><string-name><surname>Gibney</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>McGuinness</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Prendergast</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Harkin</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Connor</surname>
<given-names>TJ</given-names></string-name>. <article-title>Poly I:C-induced activation of the immune response is accompanied by depression and anxiety-like behaviours, kynurenine pathway activation and reduced BDNF expression</article-title>. <source><italic toggle="yes">Brain Behav Immun</italic></source>. <year>2013</year>;<volume>28</volume>:<fpage>170</fpage>&#x02013;<lpage>181</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbi.2012.11.010</pub-id><pub-id pub-id-type="pmid">23201589</pub-id></mixed-citation></ref><ref id="cit0035"><label>35.</label><mixed-citation publication-type="journal"><string-name><surname>Peng</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Yan</surname>
<given-names>L</given-names></string-name>, et al. <article-title>EPA is More Effective than DHA to Improve Depression-Like Behavior, Glia Cell Dysfunction and Hippcampal Apoptosis Signaling in a Chronic Stress-Induced Rat Model of Depression</article-title>. <source><italic toggle="yes">Int J Mol Sci</italic></source>. <year>2020</year>;<volume>21</volume>(<issue>5</issue>):<fpage>1769</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ijms21051769</pub-id></mixed-citation></ref><ref id="cit0036"><label>36.</label><mixed-citation publication-type="journal"><string-name><surname>Linnemann</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Lang</surname>
<given-names>UE</given-names></string-name>. <article-title>Pathways Connecting Late-Life Depression and Dementia</article-title>. <source><italic toggle="yes">Front Pharmacol</italic></source>. <year>2020</year>;<volume>11</volume>:<fpage>279</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fphar.2020.00279</pub-id><pub-id pub-id-type="pmid">32231570</pub-id></mixed-citation></ref></ref-list></back></article>
